Use of Bacille Calmette–Guerin (BCG) in multiple sclerosis
G Ristori, MG Buzzi, U Sabatini, E Giugni… - Neurology, 1999 - AAN Enterprises
G Ristori, MG Buzzi, U Sabatini, E Giugni, S Bastianello, F Viselli, C Buttinelli, S Ruggieri…
Neurology, 1999•AAN EnterprisesArticle abstract We studied the effect of Bacille Calmette–Guèrin (BCG) vaccine as an
immunomodulator in MS. According to the guidelines for clinical trials in MS, a single
crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS.
After treatment, MRI activity was significantly reduced. No major adverse effects were
reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
immunomodulator in MS. According to the guidelines for clinical trials in MS, a single
crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS.
After treatment, MRI activity was significantly reduced. No major adverse effects were
reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
Article abstract We studied the effect of Bacille Calmette–Guèrin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
American Academy of Neurology